Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02187627 · ClinicalTrials.gov registry record · Phase 1
Evaluation of [11C]RO6924963, [11C]RO6931643, and [18F]RO6958948 as Tracers for Positron Emission Tomography (PET) Imaging of Tau in Healthy and Alzheimer's Disease (AD) Participants
A Phase 1 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
NCT02187627 is a Phase 1 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 52 participants.
The verdict
NCT02187627, a Phase 1 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
Study Summary
This study is designed to obtain basic information on three PET imaging tracers developed to detect tau pathology in the brain. In this study, healthy control participants and participants with AD will be studied. Information collected will include brain and plasma kinetics, tissue distribution (in the brain), radiation dosimetry, and test-retest variability of the signal in the brain. The study will consist of Part 1, Part 2A, and Part 2B. During Part 1, imaging data will be assessed on an ongoing basis and based on data, one tracer will be prioritized over the other two tracers. The tracer selected will be further investigated in Part 2A and Part 2B.
Interventions
- DRUG [11C]RO6924963
- DRUG [11C]RO6931643
- DRUG [18F]RO6958948
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2014-08-31 |
| Est. Completion | 2016-02-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02187627
The ClinicalTrials.gov registry entry for NCT02187627 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which [11C]RO6924963 is the first listed.
NCT02187627 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02187627 about?
NCT02187627 is a clinical study titled "Evaluation of [11C]RO6924963, [11C]RO6931643, and [18F]RO6958948 as Tracers for Positron Emission Tomography (PET) Imaging of Tau in Healthy and Alzheimer's Disease (AD) Participants". This study is designed to obtain basic information on three PET imaging tracers developed to detect tau pathology in the brain. In this study, healthy control participants and participants with AD will be studied. Information collected will include brain and plasma kinetics, tissue distribution (in ...
What is the current status of trial NCT02187627?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2014-08-31. Estimated completion is 2016-02-29.
What interventions are being tested in trial NCT02187627?
The interventions under investigation include: [11C]RO6924963 (DRUG), [11C]RO6931643 (DRUG), [18F]RO6958948 (DRUG).
Who is sponsoring clinical trial NCT02187627?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.